PubMed · 2000 · 439 citations · 23 references
MedicineOncologyPharmacotherapyCancer PharmacologyMedical OncologyMolecular OncologyMalignant NeoplasmsOncogenic VirusesOncology PharmacologyOncolytic Virus TherapyToxicity ManagementAdenoviral VectorsAdenovirus BiologyAdenovirus VectorsIntratumoral AdministrationOncolytic Viral TherapyOncolytic Viral VectorsTreatment Response CriteriaTumor Response Evaluation
An E1B 55 kDa gene-deleted adenovirus, Onyx-015, which reportedly selectively replicates in and lyses p53-deficient cells, was administered by a single intratumoral injection to a total of 22 patients with recurrent head and neck cancer. The objectives of this Phase I study were to determine the safety, feasibility, and efficacy of this therapy and determine any correlation to p53 status. Six cohorts were investigated with a dose escalation from 10(7)-10(11) plaque-forming units. Toxicity was assessed using NCIC criteria. Tumor response was assessed by clinical and radiological measurement. Blood samples were taken to detect adenovirus DNA and neutralizing antibody to adenovirus. Tumor biopsies were taken to detect adenovirus by in situ hybridization. Treatment was well tolerated, with the main toxicity being grade 1/2 flu-like symptoms. Dose-limiting toxicity was not reached at the highest dose of 10(11) plaque-forming units. Twenty-one of the 22 patients treated showed an increase in neutralizing antibody to adenovirus. In situ hybridization showed viral replication in 4 of 22 patients treated, all of whom had mutant p53 tumors. Using conventional response criteria, no objective responses were observed. However, magnetic resonance imaging scans were suggestive of tumor necrosis at the site of viral injection in five patients, three of whom were classified using nonconventional criteria as partial responders, and two of whom were classified using nonconventional criteria as minor responders. Of these five cases, four had mutant p53 tumors. The response duration for the three partial responders was 4, 8, and 12 weeks. An additional eight patients had stable disease in the injected tumors lasting from 4-8 weeks. These preliminary results show that intratumoral administration of Onyx-015 is feasible, well tolerated, and associated with biological activity. Further investigation of Onyx-015, particularly with a more frequent injection protocol and in combination with systemic chemotherapy, is warranted.
23
Amplification of a gene encoding a p53-associated protein in human sarcomas
Jonathan D. Oliner, Kenneth W. Kinzler, Paul S. Meltzer et al. · Nature · 1992 · 2K citations · Full text
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
James R. Bischoff, David H. Kirn, Angelica Williams et al. · Science · 1996 · 1.8K citations
Medicine, Cancer Biology, Oncology +14
mdm2 expression is induced by wild type p53 activity.
Yaacov Barak, T. Juven, Rebecca Haffner et al. · The EMBO Journal · 1993 · 1.3K citations · Full text